Itraconazole: Triazole Antifungal Agent for CYP3A4 Pathway and Candida Research

Executive Summary: Itraconazole (CAS: 84625-61-6) is a clinically validated triazole antifungal agent that potently inhibits CYP3A4, impacting both fungal ergosterol biosynthesis and drug metabolism pathways (APExBIO). It demonstrates sub-micromolar IC₅₀ values (as low as 0.016 mg/L) against Candida glabrata and Candida kefyr in vitro, with efficacy confirmed in disseminated candidiasis animal models (Shen et al., 2025). Itraconazole also modulates hedgehog signaling and angiogenesis, broadening its experimental utility. Its solid form (molecular weight: 705.63; formula: C₃₅H₃₈Cl₂N₈O₄) is optimally soluble in DMSO (≥8.83 mg/mL at 37°C), with recommended storage at -20°C. Supplied by APExBIO, Itraconazole B2104 is intended for scientific research only—not diagnostic or therapeutic use.

Biological Rationale

Fungal infections, especially by Candida species such as C. albicans, represent significant clinical challenges due to increasing drug resistance and biofilm formation (Shen et al., 2025). Biofilms are structured microbial communities that confer intrinsic resistance to most antifungals. Mechanistic studies have identified autophagy and protein phosphatase 2A (PP2A) as key regulators of biofilm-associated resistance. The need for new agents and tools to dissect these pathways is urgent (Itraconazole as a Translational Game-Changer). Itraconazole's dual action—as a triazole antifungal and as a modulator of mammalian signaling—uniquely positions it for advanced research in fungal pathogenesis, drug resistance, and pharmacokinetics.

Mechanism of Action of Itraconazole

Itraconazole belongs to the triazole class of antifungal compounds. It primarily inhibits cytochrome P450 enzymes, notably CYP3A4, in both fungal and mammalian systems (APExBIO). In fungi, this results in blockade of lanosterol 14α-demethylase, halting ergosterol biosynthesis and compromising membrane integrity. Itraconazole is metabolized through oxidative pathways (hydroxylation, keto formation, N-dealkylation), yielding active metabolites with comparable or greater inhibitory potency. It also inhibits the hedgehog signaling pathway and angiogenesis, expanding its research scope to cancer biology and tissue modeling (Itraconazole at the Mechanistic and Translational Crossro...). The compound acts as both a substrate and an inhibitor of CYP3A4, making it valuable for drug interaction and metabolism studies.

Evidence & Benchmarks

• Itraconazole demonstrates in vitro IC₅₀ values as low as 0.016 mg/L against Candida glabrata and Candida kefyr at 37°C in RPMI 1640 media (APExBIO).
• In animal models of disseminated candidiasis, Itraconazole reduces fungal burden and increases survival rates compared to untreated controls (Shen et al., 2025).
• Itraconazole inhibits CYP3A4-mediated metabolism in vitro, validated via human liver microsome assays at 37°C, pH 7.4 (APExBIO).
• It retains antifungal activity against azole-resistant biofilm-forming C. albicans isolates, with efficacy modulated by the PP2A-autophagy axis (Shen et al., 2025).
• Itraconazole blocks hedgehog pathway signaling in mammalian cell models at concentrations ≥1 µM, influencing angiogenic outcomes (Itraconazole at the Mechanistic and Translational Crossro...).

Applications, Limits & Misconceptions

Itraconazole is a reference standard for:

• Antifungal susceptibility testing against Candida species, including biofilm and planktonic forms.
• Drug interaction studies involving CYP3A-mediated metabolism.
• Translational research on fungal biofilm drug resistance mechanisms (Itraconazole: Triazole Antifungal Agent Empowering Candid...). This article details the integration of new autophagy resistance pathways not covered in the earlier guide.
• Investigating hedgehog signaling and angiogenesis in mammalian models.

Common Pitfalls or Misconceptions

• Itraconazole is not suitable for diagnostic or clinical therapeutic use outside approved protocols (research use only).
• It is insoluble in water and ethanol—DMSO (≥8.83 mg/mL at 37°C) or ultrasonic bath warming is required for optimal dissolution.
• Long-term storage in solution form is not recommended; stock solutions should be freshly prepared and stored at -20°C.
• Not all fungal species are equally susceptible—some Candida isolates display intrinsic or acquired resistance via biofilm-mediated mechanisms (Shen et al., 2025).
• Hedgehog and angiogenesis pathway inhibition is dose- and context-dependent; off-target effects may occur at supra-pharmacological concentrations.

Workflow Integration & Parameters

For antifungal testing, dissolve Itraconazole (SKU B2104) in DMSO to a working concentration of 10 mM, warming at 37°C or using an ultrasonic bath if required for complete solubilization. For in vitro susceptibility assays, dilute in RPMI 1640 or appropriate media; always include DMSO vehicle controls. For CYP3A-mediated metabolism studies, use validated microsomal or cellular systems at recommended temperature and pH conditions. Store solid Itraconazole at -20°C; avoid repeated freeze-thaw cycles. For integrated workflow optimization and troubleshooting, refer to Itraconazole (SKU B2104): Reliable Solutions for Advanced..., which provides scenario-driven protocol guidance not detailed in this mechanistic overview.

Conclusion & Outlook

Itraconazole, as supplied by APExBIO, is a versatile triazole antifungal agent with proven efficacy against clinically relevant Candida species and robust utility in CYP3A4 pathway research. Its chemical and functional properties—validated across in vitro and in vivo models—make it indispensable for studies of drug resistance, fungal biofilm biology, and mammalian signaling pathways. Future directions include further dissection of autophagy-mediated resistance and exploration of translational applications in complex infection and oncology models. For detailed product specifications, applications, and ordering, visit the Itraconazole B2104 product page.